Local Low-dose Anti-PD-L1 Antibodies Improve Antitumor Effects in Oral Squamous Cell Carcinoma
Anticancer Research · 2024
DOI: 10.21873/anticanres.16894 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Toko Machida und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral & Maxillofacial Surgery, The Nippon Dental University Graduate School of Life Dentistry at Niigata, Niigata, Japan; machida@ngt.nd…. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Mouth Neoplasms, Head and Neck Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND/AIM: Immune checkpoint inhibitors are highly effective for treating recurrent and metastatic head and neck cancers. However, they require systemic administration and are associated with immune-related adverse events (irAEs). Reducing therapeutic antibody doses to prevent irAEs is challenging. MATERIALS AND METHODS: Mouse buccal mucosa squamous cell carcinoma cells (Sq-1979) were transplanted into the backs of mice to induce tumors. The antitumor efficacy and tumor immunohistological environment in tumor-bearing mice were compared after administering a standard dose of programmed death-ligand 1 (PD-L1) antibodies systemically (200 mg/body) or 1/10th of the standard dose (20 mg/body) directly to tumors. Mice received four doses of antibody administered in 3-day intervals. Tumor reduction rates and antitumor efficacies were evaluated 21 days after initiating treatment. CD8+T cell counts and PD-L1, PD-1, perforin, and granzyme B levels; CD25 and Foxp3 expression levels; and tumor Tregs were assessed in the resected subcutaneous tumors. RESULTS: The antitumor efficacies in the local low-dose and systemic standard-dose groups were compared with that of the control group. The efficacies of the two treatment groups were similar, and both treatment groups revealed significant antitumor effects compared to the control group. Perforin and granzyme B levels were higher in the local low-dose group (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral & Maxillofacial Surgery, The Nippon Dental University Graduate School of Life Dentistry at Niigata, Niigata, Japan; machida@ngt.ndu.ac.jp.
- Department of Oral and Maxillofacial Surgery, The Nippon Dental University School of Life Dentistry at Niigata, Niigata, Japan.
- Oral and Maxillofacial Surgery, The Nippon Dental University Niigata Hospital, Niigata, Japan.
- Department of Radiation Oncology, Central Japan International Medical Center, Minokamo, Japan.
- Department of Oral & Maxillofacial Surgery, The Nippon Dental University Graduate School of Life Dentistry at Niigata, Niigata, Japan.
Zitieren
APA
Machida, T., Sakuma, K., Fuwa, N., & Tanaka, A. (2024). Local Low-dose Anti-PD-L1 Antibodies Improve Antitumor Effects in Oral Squamous Cell Carcinoma. Anticancer Research. https://doi.org/10.21873/anticanres.16894
Vancouver
Machida T, Sakuma K, Fuwa N, Tanaka A. Local Low-dose Anti-PD-L1 Antibodies Improve Antitumor Effects in Oral Squamous Cell Carcinoma. Anticancer Research. 2024. doi:10.21873/anticanres.16894
BibTeX
@article{Machida2024,
author = {Machida, Toko and Sakuma, Kaname and Fuwa, Nobukazu and Tanaka, Akira},
title = {Local Low-dose Anti-PD-L1 Antibodies Improve Antitumor Effects in Oral Squamous Cell Carcinoma},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.16894}
}
EUVIMED